APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

KRAS Inhibitor

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

Selected research

Market Structure

Global KRAS Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173894550324 December 2025189 pages

Choose your research edition.

Industry ResearchKRAS Inhibitor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal KRAS Inhibitor Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal KRAS Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KRAS Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal KRAS Inhibitor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

The global KRAS inhibitor market is moving rapidly from an early-launch niche to a scaled targeted-oncology class. Based on APO Research’s estimates, global sales are expected to reach approximately US$0.49 billion in 2024 and grow to around US$3.18 billion by 2032, implying a strong CAGR of about 23–24% over 2025–2032. Growth is volume-driven rather than price-driven: worldwide demand is projected to increase from roughly 8.6 million to more than 78 million 120-mg-equivalent tablets over the same period, while global average net ex-factory prices gradually decline from the high-US$50s per tablet at launch to the low-US$40s by the early 2030s.

Read the full market overview

The market today is highly concentrated in a small number of tumour types and regions. Non-small-cell lung cancer (NSCLC) already accounts for the majority of KRAS inhibitor use, with colorectal cancer forming the second pillar and pancreatic plus other solid tumours contributing a small but fast-growing tail. North America remains the commercial centre of gravity, supported by high testing penetration, rapid reimbursement and comparatively high net prices. Europe scales later and at lower price points but still builds a meaningful second revenue pillar. Asia Pacific is the fastest-growing region: from a negligible base in 2021–2023, volumes expand sharply from 2024 onwards as Japan, South Korea, Australia and, critically, mainland China approve and commercialise KRAS G12C inhibitors. Because domestic products in China are priced materially below US and EU benchmarks, China’s late but rapid entry both reshapes the regional volume mix and pulls down Asia-Pacific average prices.

Competitive intensity is expected to increase as additional first-generation KRAS G12C inhibitors and next-generation molecules targeting other KRAS alleles enter the market. Amgen, Bristol Myers Squibb/Mirati, Innovent Biologics/GenFleet Therapeutics and Jacobio Pharma/Shanghai Allist Pharmaceuticals currently anchor the class, with other multinational and Chinese manufacturers developing follow-on assets. In 2024, the three largest vendors together account for well over 99% of global KRAS inhibitor revenue, but this concentration will moderate as new entrants launch, combination strategies proliferate and regional players consolidate positions in China and other emerging markets.

This report provides an overview of the global KRAS Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of KRAS Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents KRAS Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the KRAS Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

KRAS Inhibitor Segment by Company

Amgen

InventisBio/Chia Tai Tianqing Pharmaceutical

Bristol Myers Squibb/Mirati

Innovent Biologics/GenFleet Therapeutics

Jacobio Pharma/Shanghai Allist Pharmaceuticals

KRAS Inhibitor Segment by Type

Lung Cancer

Colorectal Cancer

Pancreatic Cancer

Others

KRAS Inhibitor Segment by Application

Clinic Laboratories

Hospitals

Cancer Diagnostic Centres

Others

KRAS Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KRAS Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the KRAS Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of KRAS Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of KRAS Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. KRAS Inhibitor Industry Trends Table 2. KRAS Inhibitor Industry Drivers Table 3. KRAS Inhibitor Industry Opportunities and Challenges Table 4. KRAS Inhibitor Industry Restraints Table 5. Global KRAS Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global KRAS Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global KRAS Inhibitor Sales by Manufacturers (k bottles) & (2021-2026) Table 8. Global KRAS Inhibitor Sales Market Share by Manufacturers Table 9. Global KRAS Inhibitor Average Sales Price (USD/bottle) of Manufacturers (2021-2026) Table 10. Global KRAS Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global KRAS Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global KRAS Inhibitor Manufacturers, Product Type & Application Table 13. Global KRAS Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global KRAS Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lung Cancer Table 17. Major Manufacturers of Colorectal Cancer Table 18. Major Manufacturers of Pancreatic Cancer Table 19. Major Manufacturers of Others Table 20. Global KRAS Inhibitor Sales by Type 2021 VS 2025 VS 2032 (k bottles) Table 21. Global KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 22. Global KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 23. Global KRAS Inhibitor Sales Market Share by Type (2021-2026) Table 24. Global KRAS Inhibitor Sales Market Share by Type (2027-2032) Table 25. Global KRAS Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (k bottles) Table 26. Global KRAS Inhibitor Revenue by Type (2021-2026) & (k bottles) Table 27. Global KRAS Inhibitor Revenue by Type (2027-2032) & (k bottles) Table 28. Global KRAS Inhibitor Revenue Market Share by Type (2021-2026) Table 29. Global KRAS Inhibitor Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Clinic Laboratories Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Cancer Diagnostic Centres Table 33. Major Manufacturers of Others Table 34. Global KRAS Inhibitor Sales by Application 2021 VS 2025 VS 2032 (k bottles) Table 35. Global KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 36. Global KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 37. Global KRAS Inhibitor Sales Market Share by Application (2021-2026) Table 38. Global KRAS Inhibitor Sales Market Share by Application (2027-2032) Table 39. Global KRAS Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (k bottles) Table 40. Global KRAS Inhibitor Revenue by Application (2021-2026) & (k bottles) Table 41. Global KRAS Inhibitor Revenue by Application (2027-2032) & (k bottles) Table 42. Global KRAS Inhibitor Revenue Market Share by Application (2021-2026) Table 43. Global KRAS Inhibitor Revenue Market Share by Application (2027-2032) Table 44. Global KRAS Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k bottles) Table 45. Global KRAS Inhibitor Sales by Region (2021-2026) & (k bottles) Table 46. Global KRAS Inhibitor Sales Market Share by Region (2021-2026) Table 47. Global KRAS Inhibitor Sales Forecasted by Region (2027-2032) & (k bottles) Table 48. Global KRAS Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 49. North America KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k bottles) Table 50. North America KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 51. North America KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 52. Europe KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k bottles) Table 53. Europe KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 54. Europe KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 55. Asia Pacific KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k bottles) Table 56. Asia Pacific KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 57. Asia Pacific KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 58. South America, Middle East and Africa KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k bottles) Table 59. South America, Middle East and Africa KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 60. South America, Middle East and Africa KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 61. Global KRAS Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global KRAS Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 63. Global KRAS Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 64. Global KRAS Inhibitor Revenue Market Share by Region (2021-2026) Table 65. Global KRAS Inhibitor Revenue Market Share by Region (2027-2032) Table 66. Amgen Company Information Table 67. Amgen Business Overview Table 68. Amgen KRAS Inhibitor Sales (k bottles), Price (USD/bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Amgen KRAS Inhibitor Product Portfolio Table 70. Amgen Recent Development Table 71. InventisBio/Chia Tai Tianqing Pharmaceutical Company Information Table 72. InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview Table 73. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales (k bottles), Price (USD/bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio Table 75. InventisBio/Chia Tai Tianqing Pharmaceutical Recent Development Table 76. Bristol Myers Squibb/Mirati Company Information Table 77. Bristol Myers Squibb/Mirati Business Overview Table 78. Bristol Myers Squibb/Mirati KRAS Inhibitor Sales (k bottles), Price (USD/bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio Table 80. Bristol Myers Squibb/Mirati Recent Development Table 81. Innovent Biologics/GenFleet Therapeutics Company Information Table 82. Innovent Biologics/GenFleet Therapeutics Business Overview Table 83. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales (k bottles), Price (USD/bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio Table 85. Innovent Biologics/GenFleet Therapeutics Recent Development Table 86. Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information Table 87. Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview Table 88. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales (k bottles), Price (USD/bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio Table 90. Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. KRAS Inhibitor Distributors List Table 94. KRAS Inhibitor Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. KRAS Inhibitor Product Image Figure 2. Global KRAS Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KRAS Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global KRAS Inhibitor Sales (2021-2032) & (k bottles) Figure 5. Global KRAS Inhibitor Average Price (USD/bottle) & (2021-2032) Figure 6. Global Top 5 and 10 KRAS Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lung Cancer Image Figure 9. Colorectal Cancer Image Figure 10. Pancreatic Cancer Image Figure 11. Others Image Figure 12. Global KRAS Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (k bottles) Figure 13. Global KRAS Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global KRAS Inhibitor Sales Market Share by Type (2021-2032) Figure 15. Global KRAS Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (k bottles) Figure 16. Global KRAS Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global KRAS Inhibitor Revenue Market Share by Type (2021-2032) Figure 18. Clinic Laboratories Image Figure 19. Hospitals Image Figure 20. Cancer Diagnostic Centres Image Figure 21. Others Image Figure 22. Global KRAS Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (k bottles) Figure 23. Global KRAS Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global KRAS Inhibitor Sales Market Share by Application (2021-2032) Figure 25. Global KRAS Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (k bottles) Figure 26. Global KRAS Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global KRAS Inhibitor Revenue Market Share by Application (2021-2032) Figure 28. North America KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 29. North America KRAS Inhibitor Sales Market Share by Country (2021-2032) Figure 30. U.S. KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 31. Canada KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 32. Mexico KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 33. Europe KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 34. Europe KRAS Inhibitor Sales Market Share by Country (2021-2032) Figure 35. Germany KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 36. France KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 37. U.K. KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 38. Italy KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 39. Netherlands KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 40. Asia Pacific KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 41. Asia Pacific KRAS Inhibitor Sales Market Share by Country (2021-2032) Figure 42. China KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 43. Japan KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 44. South Korea KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 45. Southeast Asia KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 46. India KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 47. Australia KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 48. South America, Middle East and Africa KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 49. South America, Middle East and Africa KRAS Inhibitor Sales Market Share by Country (2021-2032) Figure 50. Brazil KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 51. South Africa KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 52. Saudi Arabia KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 53. Turkey KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 54. Argentina KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 55. UAE KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 56. Egypt KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 57. Chile KRAS Inhibitor Sales and Growth Rate (2021-2032) & (k bottles) Figure 58. Global KRAS Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global KRAS Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Figure 61. North America KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Figure 63. Europe KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. KRAS Inhibitor Value Chain Figure 69. Manufacturing Cost Structure Figure 70. KRAS Inhibitor Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Others
Applications
  • Clinic Laboratories
  • Hospitals
  • Cancer Diagnostic Centres
  • Others
Companies covered
  • Amgen
  • InventisBio/Chia Tai Tianqing Pharmaceutical
  • Bristol Myers Squibb/Mirati
  • Innovent Biologics/GenFleet Therapeutics
  • Jacobio Pharma/Shanghai Allist Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global KRAS Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global KRAS Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global KRAS Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global KRAS Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global KRAS Inhibitor Market Dynamics
  1. 2.1 KRAS Inhibitor Industry Trends
  2. 2.2 KRAS Inhibitor Industry Drivers
  3. 2.3 KRAS Inhibitor Industry Opportunities and Challenges
  4. 2.4 KRAS Inhibitor Industry Restraints
3 KRAS Inhibitor Market by Manufacturers
  1. 3.1 Global KRAS Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global KRAS Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global KRAS Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global KRAS Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global KRAS Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global KRAS Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global KRAS Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global KRAS Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 KRAS Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 KRAS Inhibitor Tier 1, Tier 2, and Tier 3
4 KRAS Inhibitor Market by Type
  1. 4.1 KRAS Inhibitor Type Introduction
  2. 4.1.1 Lung Cancer
  3. 4.1.2 Colorectal Cancer
  4. 4.1.3 Pancreatic Cancer
  5. 4.1.4 Others
  6. 4.2 Global KRAS Inhibitor Sales by Type
  7. 4.2.1 Global KRAS Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global KRAS Inhibitor Sales by Type (2021-2032)
  9. 4.2.3 Global KRAS Inhibitor Sales Market Share by Type (2021-2032)
  10. 4.3 Global KRAS Inhibitor Revenue by Type
  11. 4.3.1 Global KRAS Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global KRAS Inhibitor Revenue by Type (2021-2032)
  13. 4.3.3 Global KRAS Inhibitor Revenue Market Share by Type (2021-2032)
5 KRAS Inhibitor Market by Application
  1. 5.1 KRAS Inhibitor Application Introduction
  2. 5.1.1 Clinic Laboratories
  3. 5.1.2 Hospitals
  4. 5.1.3 Cancer Diagnostic Centres
  5. 5.1.4 Others
  6. 5.2 Global KRAS Inhibitor Sales by Application
  7. 5.2.1 Global KRAS Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global KRAS Inhibitor Sales by Application (2021-2032)
  9. 5.2.3 Global KRAS Inhibitor Sales Market Share by Application (2021-2032)
  10. 5.3 Global KRAS Inhibitor Revenue by Application
  11. 5.3.1 Global KRAS Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global KRAS Inhibitor Revenue by Application (2021-2032)
  13. 5.3.3 Global KRAS Inhibitor Revenue Market Share by Application (2021-2032)
6 Global KRAS Inhibitor Sales by Region
  1. 6.1 Global KRAS Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global KRAS Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global KRAS Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global KRAS Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America KRAS Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe KRAS Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific KRAS Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa KRAS Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa KRAS Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global KRAS Inhibitor Revenue by Region
  1. 7.1 Global KRAS Inhibitor Revenue by Region
  2. 7.1.1 Global KRAS Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global KRAS Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global KRAS Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global KRAS Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America KRAS Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe KRAS Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific KRAS Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa KRAS Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa KRAS Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen KRAS Inhibitor Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 InventisBio/Chia Tai Tianqing Pharmaceutical
  8. 8.2.1 InventisBio/Chia Tai Tianqing Pharmaceutical Company Information
  9. 8.2.2 InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview
  10. 8.2.3 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio
  12. 8.2.5 InventisBio/Chia Tai Tianqing Pharmaceutical Recent Developments
  13. 8.3 Bristol Myers Squibb/Mirati
  14. 8.3.1 Bristol Myers Squibb/Mirati Company Information
  15. 8.3.2 Bristol Myers Squibb/Mirati Business Overview
  16. 8.3.3 Bristol Myers Squibb/Mirati KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio
  18. 8.3.5 Bristol Myers Squibb/Mirati Recent Developments
  19. 8.4 Innovent Biologics/GenFleet Therapeutics
  20. 8.4.1 Innovent Biologics/GenFleet Therapeutics Company Information
  21. 8.4.2 Innovent Biologics/GenFleet Therapeutics Business Overview
  22. 8.4.3 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio
  24. 8.4.5 Innovent Biologics/GenFleet Therapeutics Recent Developments
  25. 8.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals
  26. 8.5.1 Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information
  27. 8.5.2 Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview
  28. 8.5.3 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio
  30. 8.5.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 KRAS Inhibitor Value Chain Analysis
  2. 9.1.1 KRAS Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 KRAS Inhibitor Production Mode & Process
  6. 9.2 KRAS Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 KRAS Inhibitor Distributors
  9. 9.2.3 KRAS Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst